Monthly Archives: September 2021

Likelihood of COVID-19 vaccination by subgroups across the US: post-election trends and disparities

Posted on by

Human Vaccines & Immunotherapeutics (formerly Human Vaccines)
Volume 17, Issue 10, 2021
https://www.tandfonline.com/toc/khvi20/current

 

Article Commentary
Likelihood of COVID-19 vaccination by subgroups across the US: post-election trends and disparities
Peter G. Szilagyi, Kyla Thomas, Megha D. Shah, Nathalie Vizueta, Yan Cui, Sitaram Vangala & Arie Kapteyn
Pages: 3262-3267
Published online: 25 Jun 2021

A case control study to assess effectiveness of measles containing vaccines in preventing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in children

Posted on by

Human Vaccines & Immunotherapeutics (formerly Human Vaccines)
Volume 17, Issue 10, 2021
https://www.tandfonline.com/toc/khvi20/current

 

Article
A case control study to assess effectiveness of measles containing vaccines in preventing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in children
Nilesh Gujar, Muralidhar Tambe, Malangori Parande, Nandkumar Salunke, Ganesh Jagdale, Sarah G. Anderson, Abhijeet Dharmadhikari, Anand Lakhkar & Prasad S. Kulkarni
Pages: 3316-3321
Published online: 15 Jun 2021

Acceptability of COVID-19 vaccination in Saudi Arabia: A cross-sectional study using a web-based survey

Posted on by

Human Vaccines & Immunotherapeutics (formerly Human Vaccines)
Volume 17, Issue 10, 2021
https://www.tandfonline.com/toc/khvi20/current

 

Article
Acceptability of COVID-19 vaccination in Saudi Arabia: A cross-sectional study using a web-based survey
Saeed Mastour Alshahrani, Salem Dehom, Diaa Almutairi, Badr Saud Alnasser, Bandar Alsaif, Ahmed A. Alabdrabalnabi, Abdullah Bin Rahmah, Mastour Safar Alshahrani, Ashraf El-Metwally, Badr F Al-Khateeb, Fatmah Othman & Mohammad Mahtab Alam
Pages: 3338-3347
Published online: 08 Jul 2021

COVID-19 vaccine hesitancy: a survey in a population highly compliant to common vaccinations

Posted on by

Human Vaccines & Immunotherapeutics (formerly Human Vaccines)
Volume 17, Issue 10, 2021
https://www.tandfonline.com/toc/khvi20/current

 

Article
COVID-19 vaccine hesitancy: a survey in a population highly compliant to common vaccinations
Flora Fedele, Massimo Aria, Valeria Esposito, Maria Micillo, Gaetano Cecere, Maria Spano & Giulio De Marco
Pages: 3348-3354
Published online: 07 Jun 2021

Factors influencing COVID-19 vaccine hesitancy and acceptance among the Pakistani population

Posted on by

Human Vaccines & Immunotherapeutics (formerly Human Vaccines)
Volume 17, Issue 10, 2021
https://www.tandfonline.com/toc/khvi20/current

 

Article
Factors influencing COVID-19 vaccine hesitancy and acceptance among the Pakistani population
Farooq Ahmad Chaudhary, Basaruddin Ahmad, Muhammad Danial Khalid, Ayesha Fazal, Muhammad Mohsin Javaid & Danial Qasim Butt
Pages: 3365-3370
Published online: 08 Jul 2021

Quality over quantity: human papillomavirus vaccine information on social media and associations with adult and child vaccination

Posted on by

Human Vaccines & Immunotherapeutics (formerly Human Vaccines)
Volume 17, Issue 10, 2021
https://www.tandfonline.com/toc/khvi20/current

 

Article
Quality over quantity: human papillomavirus vaccine information on social media and associations with adult and child vaccination
Annalynn M. Galvin, Ashvita Garg, Jonathan D. Moore, Dana M. Litt & Erika L. Thompson
Pages: 3587-3594
Published online: 04 Jun 2021

15-year experience with rotavirus vaccination in Mexico: a systematic literature review

Posted on by

Human Vaccines & Immunotherapeutics (formerly Human Vaccines)
Volume 17, Issue 10, 2021
https://www.tandfonline.com/toc/khvi20/current

 

Review
15-year experience with rotavirus vaccination in Mexico: a systematic literature review
Adriana Guzman-Holst, Eduardo Ortega-Barria, Ángel Alexis Flores, Roberto Carreño-Manjarrez, Dagna Constenla & Maria Yolanda Cervantes-Apolinar
Pages: 3623-3637
Published online: 30 Jun 2021

Trends in Mortality From COVID-19 and Other Leading Causes of Death Among Latino vs White Individuals in Los Angeles County, 2011-2020

Posted on by

JAMA
September 14, 2021, Vol 326, No. 10, Pages 889-984
https://jamanetwork.com/journals/jama/currentissue

 

Research Letter
Trends in Mortality From COVID-19 and Other Leading Causes of Death Among Latino vs White Individuals in Los Angeles County, 2011-2020
Paul Simon, MD; Alex Ho, MD; Megha D. Shah, MD; et al.
free access has active quiz
JAMA. 2021;326(10):973-974. doi:10.1001/jama.2021.11945
This study compares age-adjusted mortality rates before and during the COVID-19 pandemic (2011-2020) among Latino and White individuals living in Los Angeles County.

Making Vaccines Available to Other Countries Before Offering Domestic Booster Vaccinations

Posted on by

JAMA
September 14, 2021, Vol 326, No. 10, Pages 889-984
https://jamanetwork.com/journals/jama/currentissue

 

Viewpoint
Making Vaccines Available to Other Countries Before Offering Domestic Booster Vaccinations
G. Owen Schaefer, DPhil; R. J. Leland, PhD; Ezekiel J. Emanuel, MD, PhD
free access
JAMA. 2021;326(10):903-904. doi:10.1001/jama.2021.13226
This Viewpoint highlights countries with higher concentrations of COVID-19–vaccinated residents and and excess vaccine supply vs those without, and it emphasizes the clinical and ethical reasons for prioritizing distribution of excess vaccine to underserved countries instead of keeping it for booster administration.

Effect of Training Pediatric Clinicians in Human Papillomavirus Communication Strategies on Human Papillomavirus Vaccination RatesA Cluster Randomized Clinical Trial

Posted on by

JAMA Pediatrics
September 2021, Vol 175, No. 9, Pages 886-984
https://jamanetwork.com/journals/jamapediatrics/currentissue

 

Original Investigation
Effect of Training Pediatric Clinicians in Human Papillomavirus Communication Strategies on Human Papillomavirus Vaccination RatesA Cluster Randomized Clinical Trial
Peter G. Szilagyi, MD, MPH; Sharon G. Humiston, MD, MPH; Alisa J. Stephens-Shields, PhD; et al.
JAMA Pediatr. 2021;175(9):901-910. doi:10.1001/jamapediatrics.2021.0766
This cluster randomized clinical trial evaluates the effect of online communication training for clinicians on missed opportunities for HPV vaccination rates overall and at well-child care visits and visits for acute or chronic illness and on adolescent HPV vaccination rates.

Association Between Race and COVID-19 Outcomes Among 2.6 Million Children in England

Posted on by

JAMA Pediatrics
September 2021, Vol 175, No. 9, Pages 886-984
https://jamanetwork.com/journals/jamapediatrics/currentissue

 

Association Between Race and COVID-19 Outcomes Among 2.6 Million Children in England
Defne Saatci, MD; Tom A. Ranger, PhD; Cesar Garriga, PhD; et al.
free access has active quiz
JAMA Pediatr. 2021;175(9):928-938. doi:10.1001/jamapediatrics.2021.1685
This cohort study investigates the association between race and childhood COVID-19 testing and hospital outcomes in children from family practices in England.

Violence and COVID-19 across the Globe

Posted on by

Journal of Health Care for the Poor and Underserved (JHCPU)
Volume 32, Number 3, August 2021
https://muse.jhu.edu/issue/45771

 

Table of Contents
Violence and COVID-19 across the Globe
Virginia Brennan, PhD, MAEditor, JHCPU
As the summer of 2021 simmers on, JHCPU again publishes a large collection of papers delving into the complex sea of health inequities. In this Note, to stand in for the large array of topics the issue covers, I highlight a small selection, two papers concerning violence, two on COVID-19, and two concerning sub-Saharan African nations…

Lives and Costs Saved by Expanding and Expediting Coronavirus Disease 2019 Vaccination

Posted on by

Journal of Infectious Diseases
Volume 224, Issue 6, 15 September 2021
https://academic.oup.com/jid/issue/224/6

 

COVID-2019
Editor’s Choice
Lives and Costs Saved by Expanding and Expediting Coronavirus Disease 2019 Vaccination
Sarah M Bartsch, Patrick T Wedlock, Kelly J O’Shea, Sarah N Cox, Ulrich Strych …
The Journal of Infectious Diseases, Volume 224, Issue 6, 15 September 2021, Pages 938–948, https://doi.org/10.1093/infdis/jiab233
Our study quantifies the potential value of decreasing vaccine hesitancy, increasing vaccination coverage, and how this may decrease with the time it takes to achieve coverage, emphasizing the need to reach high coverage levels as soon as possible, especially before fall/winter.

Citizen science and biomedical research

Posted on by

The Lancet Child & Adolescent Health
Oct 2021 Volume 5 Number 10 p681-766, e39-e43
https://www.thelancet.com/journals/lanchi/issue/current

 

Comment
Citizen science and biomedical research
Dana Mahr, Bruno J Strasser
…Paediatrics, even more than other medical specialties, has long been confronted with the problem that the patient’s voice is often mediated through that of their parent or caregiver. It is a characteristic of modern hospital medicine that the complex patient illness narrative has been replaced by a professional description of signs and symptoms, framed in medical categories. But nowadays, online participatory health research projects such as the COVID Symptom Study once again offer the possibility for patients to freely describe how they feel, outside of scientific and medical categories and vocabularies. Such illness narratives can now be processed automatically by analysing word frequency, as in the present paper, although more refined methods relying on artificial intelligence might better preserve the singularity of the individual patient’s experience. Finally, as with all participatory initiatives, it is important not just to ask what researchers have gained from such studies, but what was the experience of the people enrolled and whether it matched their expectations. Entering data on a smartphone app is not equivalent to discussing with a paediatrician or health-care worker who can answer further questions and concerns of participants, an especially important factor for underserved communities. In the end, the app has no emotive quality, even if those designing it do. Citizen science will continue to require a close interaction with professional medical researchers to turn unique illness experiences into research data.

Patient and general public attitudes towards clinical artificial intelligence: a mixed methods systematic review

Posted on by

Lancet Digital Health
Sep 2021 Volume 3 Number 9 e534-e611
https://www.thelancet.com/journals/landig/issue/current

 

Review
Patient and general public attitudes towards clinical artificial intelligence: a mixed methods systematic review
Albert T Young, Dominic Amara, Abhishek Bhattacharya, Maria L Wei
Summary
Artificial intelligence (AI) promises to change health care, with some studies showing proof of concept of a provider-level performance in various medical specialties. However, there are many barriers to implementing AI, including patient acceptance and understanding of AI. Patients’ attitudes toward AI are not well understood. We systematically reviewed the literature on patient and general public attitudes toward clinical AI (either hypothetical or realised), including quantitative, qualitative, and mixed methods original research articles. We searched biomedical and computational databases from Jan 1, 2000, to Sept 28, 2020, and screened 2590 articles, 23 of which met our inclusion criteria. Studies were heterogeneous regarding the study population, study design, and the field and type of AI under study. Six (26%) studies assessed currently available or soon-to-be available AI tools, whereas 17 (74%) assessed hypothetical or broadly defined AI. The quality of the methods of these studies was mixed, with a frequent issue of selection bias. Overall, patients and the general public conveyed positive attitudes toward AI but had many reservations and preferred human supervision. We summarise our findings in six themes: AI concept, AI acceptability, AI relationship with humans, AI development and implementation, AI strengths and benefits, and AI weaknesses and risks. We suggest guidance for future studies, with the goal of supporting the safe, equitable, and patient-centred implementation of clinical AI.

Economic impact of tuberculosis mortality in 120 countries and the cost of not achieving the Sustainable Development Goals tuberculosis targets: a full-income analysis

Posted on by

Lancet Global Health
Oct 2021 Volume 9 Number 10 e1336-e1473
https://www.thelancet.com/journals/langlo/issue/current

 

Articles
Economic impact of tuberculosis mortality in 120 countries and the cost of not achieving the Sustainable Development Goals tuberculosis targets: a full-income analysis
Sachin Silva, et al.

COVID-19 vaccine equity and booster doses

Posted on by

Lancet Infectious Diseases
Sep 2021 Volume 21 Number 9 p1193-1332, e258-e301
https://www.thelancet.com/journals/laninf/issue/current

 

Editorial
COVID-19 vaccine equity and booster doses
The Lancet Infectious Diseases
The debate on COVID-19 vaccine equity has been long-running, and we have previously weighed in on the topic. However, the facts that (1) by Aug 9, only 12·6 million of the 4·46 billion doses administered globally were in low-income countries, (2) 3·65 billion have been administered in high-income (HICs) and upper-middle-income countries, and (3) WHO Director-General Tedros Adhanom Ghebreyesus actually had to issue a plea for a moratorium on third-dose boosters in HICs on Aug 4, mean that we, again, need to add our voice to the demand for equitable access to vaccines.

“No one is safe until everyone is safe” has become the mantra of the COVID-19 pandemic, with good reason. Unmitigated transmission means rampant viral replication, which in turn means infinite opportunities for the emergence of new, more transmissible variants that could escape natural or vaccine-induced immunity. A perverse social experiment would be to allow the virus to continue ripping through low-income and lower-middle-income countries (LMICs), where people tend to live in close proximity and infection prevention strategies are difficult to implement because much of the populations rely on hand-to-mouth income (India being a case-in-point), while seeing how quickly HICs can redesign vaccines to counter yet another variant that has emerged from LMICs. Beyond the moral argument, this approach would make no economic sense: if many final goods in HICs rely on raw materials and intermediate goods from LMICs, and if LMICs cannot provide these materials because their populations are dying from COVID-19 or are prevented from working because of lockdowns, how long do HICs think that they can keep their own economies running? The RAND corporation estimates that HICs would see a return of US$4·8 for every $1 spent on supplying vaccines to LMICs, and the Global Dashboard for Vaccine Equity shows that if vaccine distribution were uniform, HICs still stand to gain the most. Additionally, while HICs hoard their precious vaccines, China and Russia, two ambitious political entities, have been only too happy to offer their vaccines and strengthen their spheres of influence in Africa, South America, southeast Asia, the Middle East, and eastern Europe.

The administration of a third dose is motivated by fear of the B.1.617.2 (delta) variant but the intensity of this fear is unfounded, as there is now evidence that vaccines licensed in HICs are effective enough against it. Conversely, there is no definitive evidence if, and when, a third dose is necessary, and much-needed trials—the only context in which third-dose administration should be acceptable—are eagerly awaited. There is some evidence of waning antibody titres, which is an axiom of any vaccine administration that does not equal waning cellular immunity. Although the world has ubiquitously grappled with the plague of vaccine hesitancy, the level of coverage in HICs and the rates of administration of new doses should now be sufficient to allow the redirection of surplus doses to those who have none via the COVAX initiative. It is deeply ironic that COVID-19 vaccine acceptance might actually be much higher in LMICs than in HICs. A point must also be made about increasingly risky behaviour—it is irresponsible to encourage relaxation of basic physical distancing measures such as mask wearing in public or confined spaces even for vaccinated individuals, which may well be contributing to a large proportion of breakthrough infections.

A crucial problem for getting vaccines to LMICs is an interrupted cold chain. This is the case in Africa, where many communities live without continuous power supplies, and freezers that cost up to $20 000 are unaffordable. While capacity building is ongoing, countries could focus on donating and administering vector vaccines that are easier to store than mRNA vaccines and are sufficiently safe and effective, particularly in older individuals. Preliminary evidence from the Com-COV trial shows that heterologous vaccination is safe and induces robust immune responses, a viable option for countries that cannot rely on a steady stream of vaccines. There have been calls, reasonable in a time of global catastrophe, to waive intellectual property rights to facilitate local vaccine manufacturing, which should currently focus on LMICs with sufficiently robust regulatory capacities to ensure the quality of local production, as argued by the Center for Global Development. Vaccine donors and corporations can think about how to help with these issues in the short and long terms.

Vulnerable people in HICs have already been prioritised; vulnerable people in LMICs cannot wait until 2023 for their turn, and this wait is in the best interest of no one.

Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1–2, dose-ranging study

Posted on by

Lancet Infectious Diseases
Sep 2021 Volume 21 Number 9 p1193-1332, e258-e301
https://www.thelancet.com/journals/laninf/issue/current

 

Articles
Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1–2, dose-ranging study
Paul A Goepfert, et al.

Immunogenicity and safety of a tri-antigenic versus a mono-antigenic hepatitis B vaccine in adults (PROTECT): a randomised, double-blind, phase 3 trial

Posted on by

Lancet Infectious Diseases
Sep 2021 Volume 21 Number 9 p1193-1332, e258-e301
https://www.thelancet.com/journals/laninf/issue/current

 

Immunogenicity and safety of a tri-antigenic versus a mono-antigenic hepatitis B vaccine in adults (PROTECT): a randomised, double-blind, phase 3 trial
Timo Vesikari,et al. for the PROTECT Study Group

Safety and immunogenicity of a purified inactivated Zika virus vaccine candidate in healthy adults: an observer-blind, randomised, phase 1 trial

Posted on by

Lancet Infectious Diseases
Sep 2021 Volume 21 Number 9 p1193-1332, e258-e301
https://www.thelancet.com/journals/laninf/issue/current

 

Safety and immunogenicity of a purified inactivated Zika virus vaccine candidate in healthy adults: an observer-blind, randomised, phase 1 trial
Htay-Htay Han, et al.

Impact of the introduction of pneumococcal conjugate vaccination on invasive pneumococcal disease and pneumonia in The Gambia: 10 years of population-based surveillance

Posted on by

Lancet Infectious Diseases
Sep 2021 Volume 21 Number 9 p1193-1332, e258-e301
https://www.thelancet.com/journals/laninf/issue/current

 

Impact of the introduction of pneumococcal conjugate vaccination on invasive pneumococcal disease and pneumonia in The Gambia: 10 years of population-based surveillance
The Gambia Pneumococcal Surveillance Group,
Grant A Mackenzie, et al.
Open Access

BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers

Posted on by

Lancet Respiratory Medicine
Aug 2021 Volume 9 Number 8 p803-936, e69-e87
https://www.thelancet.com/journals/lanres/issue/current

 

Articles
BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers
Yaniv Lustig, et al

Behavioural nudges increase COVID-19 vaccinations

Posted on by

Nature
Volume 597 Issue 7876, 16 September 2021
https://www.nature.com/nature/volumes/597/issues/7875

 

Article | 02 August 2021 | Open Access
Behavioural nudges increase COVID-19 vaccinations
Two randomized controlled trials demonstrate the ability of text-based behavioural ‘nudges’ to improve the uptake of COVID-19 vaccines, especially when designed to make participants feel ownership over their vaccine dose.
Hengchen Dai, Silvia Saccardo, Daniel M. Croymans

FoGS provides a public FAQ repository for social and behavioral genomic discoveries

Posted on by

Nature Genetics
Volume 53 Issue 9, September 2021
https://www.nature.com/ng/volumes/53/issues/9

 

Comment | 06 September 2021
FoGS provides a public FAQ repository for social and behavioral genomic discoveries
Here we introduce ‘FAQs on Genomic Studies’ (FoGS), an open-access repository of explanatory documents that accompany genomic analyses in social and behavioral genomics. For fields such as social and behavioral genomics that are shaped by an ugly history and uncertain future, socially and ethically responsible research and research communication are crucial. FoGS amplifies one such approach towards responsible research communication.
Daphne Oluwaseun Martschenko, Benjamin W. Domingue, Sam Trejo

Balancing incentives and disincentives for vaccination in a pandemic

Posted on by

Nature Medicine
Volume 27 Issue 9, September 2021
https://www.nature.com/nm/volumes/27/issues/9

 

Comment | 06 September 2021
Balancing incentives and disincentives for vaccination in a pandemic
Mandates and incentives are being considered to increase uptake of vaccines against COVID-19, but payment for vaccination may be the fairest approach.
Julian Savulescu, Jonathan Pugh, Dominic Wilkinson

mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar

Posted on by

Nature Medicine
Volume 27 Issue 9, September 2021
https://www.nature.com/nm/volumes/27/issues/9

 

Article | 09 July 2021
mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar
A matched test-negative, case-control study using real-world data from a predominantly working-age population demonstrates efficacy of the mRNA-1273 vaccine to be 100% and 96.4% against the B.1.1.7 (Alpha) and B.1.351 (Beta) SARS-CoV-2 variants of concern, respectively.
Hiam Chemaitelly, Hadi M. Yassine, Laith J. Abu-Raddad

Safety, immunogenicity and efficacy of PfSPZ Vaccine against malaria in infants in western Kenya: a double-blind, randomized, placebo-controlled phase 2 trial

Posted on by

Nature Medicine
Volume 27 Issue 9, September 2021
https://www.nature.com/nm/volumes/27/issues/9

 

Article | 13 September 2021
Safety, immunogenicity and efficacy of PfSPZ Vaccine against malaria in infants in western Kenya: a double-blind, randomized, placebo-controlled phase 2 trial
The PfSPZ Vaccine does not protect infants from infection with Plasmodium falciparum, the major cause of malaria.
Martina Oneko, Laura C. Steinhardt, Robert A. Seder

SARS-CoV-2 and HIV-1 — a tale of two vaccines

Posted on by

Nature Reviews Immunology
Volume 21 Issue 9, September 2021
https://www.nature.com/nri/volumes/21/issues/9

 

Comment | 16 July 2021
SARS-CoV-2 and HIV-1 — a tale of two vaccines
It took roughly 1 year for a COVID-19 vaccine to become available, yet, four decades after the first patient with HIV was described, we do not yet have a vaccine for HIV. Here, Barton Haynes examines the biological reasons why vaccine development for HIV is so exceptionally challenging.
Barton F. Haynes

Cost-effectiveness analysis of an intervention project engaging Traditional and Religious Leaders to improve uptake of childhood immunization in southern Nigeria

Posted on by

PLoS One
http://www.plosone.org/
[Accessed 18 Sep 2021]

 

Cost-effectiveness analysis of an intervention project engaging Traditional and Religious Leaders to improve uptake of childhood immunization in southern Nigeria
Angela E. Oyo-Ita, Patrick Hanlon, Ogonna Nwankwo, Xavier Bosch-Capblanch, Dachi Arikpo, Ekperonne Esu, Christian Auer, Martin Meremikwu
Research Article | published 16 Sep 2021 PLOS ONE
https://doi.org/10.1371/journal.pone.0257277

Incentives can spur COVID-19 vaccination uptake

Posted on by

PNAS – Proceedings of the National Academy of Sciences of the United States
September 07, 2021; vol. 118 no. 36
https://www.pnas.org/content/118/36

 

Brief Reports
Incentives can spur COVID-19 vaccination uptake
Heike Klüver, Felix Hartmann, Macartan Humphreys, Ferdinand Geissler, and Johannes Giesecke
PNAS September 7, 2021 118 (36) e2109543118; https://doi.org/10.1073/pnas.2109543118

The impact of a universal human papilloma virus (HPV) vaccination program on lower genital tract dysplasia and genital warts

Posted on by

Preventive Medicine
Volume 150 September 2021
https://www.sciencedirect.com/journal/preventive-medicine/vol/150/suppl/C

 

Research article Abstract only
The impact of a universal human papilloma virus (HPV) vaccination program on lower genital tract dysplasia and genital warts
M. Clark, N. Jembere, R. Kupets
Article 106641

Applying the AFIX Quality Improvement Model to Increase Adult Immunization in Wisconsin

Posted on by

Public Health Reports
Volume 136 Issue 5, September/October 2021
https://journals.sagepub.com/toc/phrg/136/5

 

Research
Applying the AFIX Quality Improvement Model to Increase Adult Immunization in Wisconsin
Stephanie M. Borchardt, PhD, MPH, Kailynn Mitchell, MPH, Taylor Larson, MPH, Ellen Ehlers, MSW, Stephanie L. Schauer, PhD
First Published February 9, 2021; pp. 603–608

Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants

Posted on by

Science
Volume 373| Issue 6561| 17 Sep 2021
https://www.science.org/toc/science/current

 

Reports
Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants
BY Amarendra Pegu et al.
13 Aug 2021: 1372-1377
Open Access
Most individuals vaccinated with mRNA-1273 develop functional antibodies against SARS-CoV-2 variants for at least 6 months.

Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates

Posted on by

Science
Volume 373| Issue 6561| 17 Sep 2021
https://www.science.org/toc/science/current

 

Research Articles
Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates
BY Kizzmekia S. Corbett et al.
17 Sep 2021
Open Access
mRNA-1273 vaccine–induced antibody responses are a mechanistic correlate of protection against SARS-CoV-2 infection in nonhuman primates.